Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Tiziana Life Sciences Ltd (TLSA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 6.05 M | -936,000 | 6.65 M | 12.18 M | 7.34 M |
| 2022 | -17,757,000 | 6.91 M | 26.48 M | 24.28 M | |
| 2021 | -40,831,000 | 7.55 M | 48.83 M | 48.68 M | |
| 2020 | -65,156,657 | 8.25 M | 70.55 M | 70.06 M | |
| 2019 | 616.25 K | 7.85 M | 2.37 M | 1.5 M |